Toronto Stock Exchange Symbol: DND
MISSISSAUGA, ON, Feb. 21, 2013 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:
DND) (OTC: CPHMF), today announced it will host a conference call for
its Q4 and Year-End 2012 financial results on Friday, March 1, 2013.
Q4 AND YEAR-END 2012 CONFERENCE CALL
WHEN: Friday, March 1, 2013 at 8:30AM ET
CONFERENCE CALL/WEBCAST: You can join the call by dialing 647-427-7450
or 1-888-231-8191. A live audio webcast will be available through http://www.cipherpharma.com or http://www.newswire.ca. An archived replay of the webcast will be available for 365 days.
About Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals (TSX: DND; OTC: CPHMF) is a growing specialty
pharmaceutical company that commercializes novel formulations of
successful, currently marketed molecules. Cipher's strategy is to
in-license clearly differentiated products, advance them through the
clinical development and regulatory approval stages, and out-license to
international marketing partners. Cipher's first product is a
fenofibrate formulation marketed in the United States as Lipofen®.
Cipher's second product, an extended-release tramadol, is marketed in
the United States as ConZip® and in Canada as Durela®. Cipher's third
product, a novel formulation of the acne treatment isotretinoin, was
approved by the FDA in May 2012 and launched in the United States in Q4
2012 as Absorica™. The product was also recently approved by Health
Canada and Cipher expects to launch it as Epuris™ in Canada in early Q3
For more information, please visit www.cipherpharma.com.
SOURCE: Cipher Pharmaceuticals Inc.
For further information:
(416) 815-0700 ext 278
(416) 815-0080 fax
President and CEO
(905) 602-5840 ext 324
(905) 602-0628 fax